.Attribute Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average follow-up of 11 months, people with metastatic stomach cysts who got biomarker-matched therapies based on distributing tumor DNA profiling showed a greater scientific benefit than those getting unparalleled therapy.